Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/798
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorCONDI, F. L. F.-
dc.contributor.authorSOARES JR., J. M.-
dc.contributor.authorTEODORO, W. R.-
dc.contributor.authorVELOSO, A. P.-
dc.contributor.authorPARRA, E. R.-
dc.contributor.authorSIMOES, M. de Jesus-
dc.contributor.authorBARACAT, E. C.-
dc.date.accessioned2013-07-30T15:08:56Z-
dc.date.available2013-07-30T15:08:56Z-
dc.date.issued2012-
dc.identifier.citationCLIMACTERIC, v.15, n.5, p.441-448, 2012-
dc.identifier.issn1369-7137-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/798-
dc.description.abstractObjective To evaluate the action of conjugated equine estrogen, raloxifene and isolated or combined genistein-rich soy extracts on collagen fibers in the bones of oophorectomized rats. Materials and methods Seventy female rats received testosterone propionate (0.1 mu g/g) on the 9th day after birth. At 6 months of age, the rats were administered the vehicle (propylene glycol, 0.5 ml/day), and ten of the rats were randomly chosen to comprise the non-oophorectomized control group (GI). The other 60 rats were ovariectomized and randomized into six groups of ten as follows: GII, vehicle; GIII, conjugated equine estrogen (CEE), 50 mu g/kg/day; GIV, raloxifene (RAL), 0.75 mg/kg/day; GV, genistein-rich soy extract (GSE), 300 mg/kg/day; GVI, CEE + GSE, 50 mu g/kg/day + 300 mg/kg/day; and GVII, CEE + RAL, 50 mu g/kg/day + 0.75 mg/kg/day. Three months after surgery, the drugs were administered for 60 consecutive days. All rats were euthanized, and their left tibiae were removed for histological routine. The histological sections were stained with hematoxylin-eosin, and picrosirius for evaluating bone microarchitecture. Types I and II collagen fibers were analyzed by immunofluorescence. Data analysis was carried out with ANOVA and Tukey's test. Results Collagen reduction was significant in the GIII animals when compared to the other groups (p < 0.05). There was no significant difference in the thickness of collagen fibers among the groups. There was a greater quantity of type III collagen in GVI than in the other groups. Conclusion Our data indicate that conjugated equine estrogen improves bone quality because it increases the quantity of type I collagen while reducing the quantity of thin collagen fibers. In addition, the combination of CEE and raloxifene or genistein-rich soy extract is not as efficient as CEE itself to improve bone quality.-
dc.description.sponsorshipFAPESP, Sao Paulo, Brazil-
dc.description.sponsorshipCAPES, Brasilia, Brazil-
dc.language.isoeng-
dc.publisherINFORMA HEALTHCARE-
dc.relation.ispartofClimacteric-
dc.rightsrestrictedAccess-
dc.subjectCONJUGATED EQUINE ESTROGEN-
dc.subjectRALOXIFENE-
dc.subjectGENISTEIN-RICH SOY EXTRACT-
dc.subjectBONE-
dc.subjectFEMALE RATS-
dc.subject.otherovariectomized rats-
dc.subject.othergenistein-
dc.subject.otherreceptor-
dc.subject.othertissue-
dc.subject.otherphytoestrogens-
dc.subject.otherfibers-
dc.subject.othermodel-
dc.subject.otherbeta-
dc.titleThe effects of conjugated estrogen, raloxifene and soy extract on collagen in rat bones-
dc.typearticle-
dc.rights.holderCopyright INFORMA HEALTHCARE-
dc.identifier.doi10.3109/13697137.2011.624213-
dc.identifier.pmid22208761-
dc.subject.wosObstetrics & Gynecology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalSIMOES, M. de Jesus:Univ Fed Sao Paulo, Dept Histol & Cellular Biol, Sao Paulo, Brazil-
hcfmusp.description.beginpage441-
hcfmusp.description.endpage448-
hcfmusp.description.issue5-
hcfmusp.description.volume15-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000308942500006-
hcfmusp.origem.id2-s2.0-84866352758-
hcfmusp.publisher.cityLONDON-
hcfmusp.publisher.countryENGLAND-
hcfmusp.relation.referenceAlbertazzi P, 2002, CLIMACTERIC, V5, P190, DOI 10.1080/713605224-
hcfmusp.relation.referenceAnderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593-
hcfmusp.relation.referenceAnderson JJB, 1998, P SOC EXP BIOL MED, V217, P345-
hcfmusp.relation.referenceArcher DF, 2010, DRUG AGING, V27, P533, DOI 10.2165/11316000-000000000-00000-
hcfmusp.relation.referenceBaracat EC, 1998, MENOPAUSE, V5, P263, DOI 10.1097/00042192-199805040-00089-
hcfmusp.relation.referenceBryant HU, 1996, OSTEOPOROS INT S1, V6, P233, DOI 10.1007/BF02500468-
hcfmusp.relation.referenceCai DJ, 2005, J BONE MINER RES, V20, P828, DOI 10.1359/JBMR.041236-
hcfmusp.relation.referenceCarrin VS, 2006, OSTEOPOROS INT 0421, V17, P319-
hcfmusp.relation.referenceChiechi KM, 1999, INT J GYNECOL, V67, P39-
hcfmusp.relation.referenceDeroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987-
hcfmusp.relation.referenceKEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P59-
hcfmusp.relation.referenceKuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863-
hcfmusp.relation.referenceKuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252-
hcfmusp.relation.referenceMESSINA MJ, 1994, NUTR CANCER, V21, P113-
hcfmusp.relation.referenceMoraes AVC, 2006, REV BRAS GINECOL OBS, V28, P101-
hcfmusp.relation.referenceNachtigall L, 2001, J BR MENOPAUSE SO S1, P8-
hcfmusp.relation.referenceReinwald S, 2010, J OSTEOPOROSIS-
hcfmusp.relation.referenceRizk DEE, 2008, INT UROGYNECOL J, V19, P547, DOI 10.1007/s00192-007-0462-1-
hcfmusp.relation.referenceSetchell KD, 2001, J NUTR, V131, P1362-
hcfmusp.relation.referenceShen ZL, 2008, BIOPHYS J, V95, P3956, DOI 10.1529/biophysj.107.124602-
hcfmusp.relation.referenceSliwinski L, 2009, ACTA BIOCHIM POL, V56, P261-
hcfmusp.relation.referenceSwaminathan R, 2001, CLIN CHIM ACTA, V313, P95, DOI 10.1016/S0009-8981(01)00656-8-
hcfmusp.relation.referenceTamura N, 2005, FERTIL STERIL, V84, P1277, DOI 10.1016/j.fertnstert.2005.06.017-
hcfmusp.relation.referenceVasilceac FA, 2011, RHEUMATOL INT, V31, P737, DOI 10.1007/s00296-010-1371-z-
hcfmusp.relation.referenceVelosa APP, 2007, REV BRAS REUMATOL, V47, P401, DOI 10.1590/S0482-50042007000600003-
hcfmusp.relation.referenceViguet-Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198-005-2035-9-
hcfmusp.relation.referenceWeitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550-
hcfmusp.relation.referenceYoles I, 2003, MENOPAUSE, V10, P522, DOI 10.1097/01.GME.0000064864.58809.77-
dc.description.indexMEDLINE-
hcfmusp.remissive.sponsorshipCAPES-
hcfmusp.remissive.sponsorshipFAPESP-
hcfmusp.remissive.sponsorshipCAPES-
hcfmusp.remissive.sponsorshipFAPESP-
hcfmusp.lim.ref2012-
hcfmusp.citation.scopus9-
hcfmusp.scopus.lastupdate2024-04-12-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - FM/MOG
Departamento de Obstetrícia e Ginecologia - FM/MOG

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia

Artigos e Materiais de Revistas Científicas - LIM/58
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular


Files in This Item:
File Description SizeFormat 
art_CONDI_The_effects_of_conjugated_estrogen_raloxifene_and_soy_2012.PDF
  Restricted Access
publishedVersion (English)487.83 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.